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Abstract
MicroRNAs are a class of small non-coding RNAs involved in the transcrip-
tional and post-transcriptional regulation of gene expression. The function
of miRNAs in liver disease including hepatocellular carcinoma (HCC), hepa-
titis, and alcoholic liver disease, have been widely studied and extensively
reviewed. Increasing evidence demonstrates that miRNAs also play a critical
role in normal liver development and in the fine-tuning of fundamental bio-
logical liver processes. In this review, we highlight the most recent findings
on the role of miRNAs in liver specification and differentiation, liver cell
development, as well as in the many metabolic functions of the liver, includ-
ing glucose, lipid, iron and drug metabolism. These findings demonstrate an
important role of miRNAs in normal liver development and function. Fur-
ther researches will be needed to fully understand how miRNAs regulate liver
generation and metabolic function, which should then lead to greater
insights in liver biology and perhaps open up the possibility to correct errors
that cause liver diseases or metabolic disorders.
The liver is the largest gland in mammals serving as an
endocrine and exocrine organ with numerous functions,
including carbohydrate, lipid and amino-acid metabo-
lism, urea synthesis, detoxification of drugs and toxic
endogenous compounds, bile production and plasma
protein secretion (1). As the liver is such a vital organ to
life, its dysfunction or failure is associated with high lev-
els of morbidity and mortality. Hence, gaining insights
in how the different cell components of the liver develop
and how its vast metabolic functions are developed and
maintained is of great importance.
The liver consists of different types of cells, such as
hepatocytes, cholangiocytes, liver sinusoidal endothelial
cells (LSECs), hepatic stellate cells (HSCs) and kupffer
cells (KCs). Less is known regarding the developmental
processes underlying the generation of the mesodermal
LSEC and HSC compartment, while the development of
the endodermal compartments of the liver are inten-
sively studied. There are four major steps in hepatocyte
(endodermal origin) formation: formation of definitive
endoderm (DE); hepatic specification; formation of
hepatoblasts and maturation of hepatocytes (2). Extensive
and intensive studies have demonstrated that liver
development is a tightly regulated, complicated process.
miRNAs are reported to be involved in almost every
aspect of biology, including cell differentiation, prolifer-
ation, metabolism and apoptosis, in tumour formation,
as well as in mobile genetic element stability and viral
infection (3). It is estimated that at least one-third of
human genes is regulated by miRNAs (4). Thus, it is not
surprising that many organ development and differenti-
ation processes are tightly regulated by miRNAs. Indeed,
increasing evidences demonstrate that miRNAs play
important roles in regulating liver development and
homeostasis, as well as in many kinds of liver diseases.
The critical roles of miRNAs in liver disease have
been extensively reviewed (5–9), especially in liver can-
cer (10–13), liver fibrosis (14), alcoholic liver disease
(15), hepatitis (16–18), as well as induced liver injury
(19). However, few articles have specifically focused on
the roles of miRNAs during liver development and in
fundamental liver functions. In this review, we will
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highlight studies of miRNAs that regulate normal liver
development and liver function, and propose some
open questions in this field, which may further our
understanding of liver development and function, and
contribute to potential therapeutic approaches.
Global impact of microRNAs on Liver development
DICER1 and DGCR8 are two key factors in the miRNA-
signalling pathway. Constitutive disruption of either of
them will lead to a global loss of miRNAs (20). Loss of
DICER in mice causes early embryonic lethality at E7.5
because of the defects in proliferation and incapability
of maintaining pluripotency in extraembryonic tissues
(21, 22). Hepatoblast/hepatocyte-specific DICER1 and
DGCR8 conditional knock-out (cKO) mice were,
respectively, generated to elucidate the global function
of miRNAs in liver development.
Dicer1 knock out and liver development
Hand et al. generated hepatoblast-specific DICER1 con-
ditional knock-out mice by crossing the Dicer1flox/flox
mice with AfpCre mice (23), wherein DICER1 was
deleted in hepatoblast-derived cells in AfpCre;Dicer1flox/
flox mutants. Alfp; Dicer1 cKO mice were born alive and
showed no phenotype at birth compared to wild-type
(WT) mice, even if there was efficient disruption of
DICER1 in hepatocytes. The liver enriched miRNAs,
such as miR-122, miR-192 and miR-194 were signifi-
cantly down-regulated. Between 2–4 months of age
mutant mice exhibited progressive hepatocyte damage
with prominent steatosis, depletion of glycogen storage
and increased levels of serum alanine aminotransferase
and aspartate aminotransferase. Some proliferation-pro-
moting and hepatoblast-specific genes were also
increased. This resulted in increased hepatocyte prolifer-
ative activity and increased liver mass, as well as over-
whelming apoptosis (23). Sekine et al. also generated a
mouse model wherein Dicer was specifically eliminated
from mature hepatocytes by mating Dicerflox/flox mice
with AlbCre mice (24). As was seen for AfpCre; Dicerflox/
flox mice, increased growth-promoting gene expression
and robust expression of fetal stage-specific genes was
seen, and hepatocytes from AlbCre; Dicerflox/flox were
susceptible to apoptosis. At 3 weeks, livers contained
chiefly hepatocytes without DICER expression, however,
mice surviving long-term had livers consisting of
DICER expressing hepatocytes that had escaped the
Cre-mediated deletion. Nevertheless, the remaining
DICER negative hepatocytes lead, as in the AfpCre;
Dicer1flox/flox mice, to hepatocarcinomas in two-thirds of
animals at 1 year (24). These results suggest that DICER
and miRNAs play critical roles in hepatocyte matura-
tion, regeneration, hepatic gene regulation and tumour
suppression in the liver.
Careful analysis of the DICER negative cells in Alb/
Cre; Dicerflox/flox mice at 3 weeks of age demonstrated
that miRNAs are also involved in establishing/maintain-
ing liver zonation (25). Although the perivenous loca-
tion marker gene glutamine synthetase (GS) was found
perivenously in Alb/Cre; Dicerflox/flox mice, its expression
extended beyond its normal boundaries. By contrast,
some periportal marker genes completely lost their
localized expression patterns and were diffusely
expressed throughout the entire lobule (25). Thus, Dicer
is required for the establishment of proper liver zona-
tion. However, no direct evidence shows specific miR-
NAs are involved in regulating liver zonation. Thus,
further exploration is needed to study the function of
specific miRNAs in mediating liver zonation.
DGCR8 knock-out and liver development
No studies have been performed wherein DGCR8 has
specifically been eliminated from hepatocytes. However,
studies have been done in DGCR8 vascular smooth
muscle specific cKO mice. The mutant mice had hepa-
tomegaly and liver haemorrhage compared with control
mice. Surprisingly, no defects in hepatocytes were seen
as expected (26). To fully elucidate the role of DGCR8
in liver/hepatocyte development, a DGCR8 knock-out
liver model should be generated in the future.
MicroRNAs and liver derived cell development
Definitive endoderm formation
Fu et al. evaluated dynamic miRNA changes during DE
formation using murine embryonic stem cells (mESCs)
as a model (27). They found a progressively increasing
number of miRNAs to be up and down-regulated, fol-
lowing addition of Wnt3-a and Activin-A on days 1–5.
Amongst them were miR-196a, miR-196b and miR-24-
2*, also known to be up-regulated during Na-Butyrate
mediated DE specification from human (h)ESCs (28),
as well as miR-222, miR-338-5p and miR-340-3p
(Fig. 1a). Forced expression of a combination of
miRNAs (miR-181c/338-5p/222/196a/196b/let-7e), en-
hanced Activin-A mediated DE formation, at least in
part by modifying the expression of histone deacetylase
9 (HDAC9), which is involved in histone acethylation of
promoter regions of DE specific genes. A similar study
was performed by Hinton et al. using two hESC lines
(29). In a third study on hESC, Kim et al. compared
hESC, DE and ESC-derived ‘mature hepatocytes’ (30).
One mouse ESC (TCL-1) and 5 different human ESC
lines (HES-1, HES-2, H9, CyT49 and CHA4) were used
in the four studies, with little concordance between the
results. As shown in Figure 1a, no miRNA was consis-
tently up-regulated in DE cells compared with undiffer-
entiated ESCs; one miRNA, miR-375, was significantly
up-regulated in DE derived from four of six lines; and
six miRNAs (miR-10a/24/218/371-3p/371-5p/373) were
significantly up-regulated in two of the six DE progeny.
For down-regulated miRNAs, miR-520 family was
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significantly down-regulated in DE from three cell lines,
and miR-204/525-5p in two (28–30). Different cell lines
and differentiation protocol used in these studies may
be the reason for the variety of the up/down-regulated
miRNAs. Further analysis remains to be done to
uncover which of the up/down regulated miRNAs con-
tribute to DE formation.
Hepatoblast migration and maturation
During the delamination of hepatoblasts from the liver
diverticulum and invasion in the STM, hepatoblasts
exhibit morphological changes reminiscent of epithe-
lium to mesenchymal transition (EMT). Although the
precise factors that govern this process are not fully
known, it is in general believed that TGFb plays an
important role in EMT during development (31).
Using the murine AML-12 hepatocyte cell line, Zhang
et al. demonstrated that levels of miR-30b, miR-30c,
miR-30d, miR-30e but not miR-30a support increased
expression of snail homolog 1 (SNAIL1) (32), which
resulted in the down-regulation of E-cadherin, the
marker gene of epithelial cells (Fig. 1b). miR-30 family
were also reported to suppress the EMT processes in
prostate cancer (33), which suggests miR-30 may be a
therapeutic target as a tumour suppressor. By micro-
array profiling analysis, Wei et al. found that expres-
sion of miR-302b and miR-20a were higher in mouse
E8.5 foregut (containing liver progenitor cells) than in
E14.5 hepatoblasts (34). Target analysis demonstrated
that miR-302b reduces the expression of transforming
growth factor beta receptor II (TGFBR2, a type II
receptor required for TGFb ligand signalling) and K
(Lysine) acetyltransferase 2B (KAT2B, a histone acetyl-
transferase interacting directly with the intracellular
TGFb signalling component – SMAD3) (34). These stud-
ies suggest that migration from the liver primordium
into the STM may be governed by TGF-b mediated
EMT, and that this might be regulated by miR-30,
miR-302 and miR-20.
Other signals that govern this initial migration step
include hepatocyte nuclear factor 6 (HNF6, also known
as Onecut-1 or OC1) and OC2 (35, 36). miR-495 and
miR-218 [also identified to be up-regulated during DE
specification(27)] actively regulate expression of OC1
and OC2 (37). miR-495 and miR-218 are expressed at
low levels in e8.5 endodermal epithelium and in e9.5 in
hepatic buds emerging from the endoderm, but are
Definitive
endodermESC
mESC/TCL-1 miR-196a, miR-196b, 
miR-24-2*, let-7e, 
miR-181c, miR-290-3p
… 
miR-301b, miR-804,
miR-219, miR-1224,
miR-712*, miR-483
… 
hESC/HES1 miR-24, let-7b, 
miR-10a, let-7c, 
miR-346, let-7d*
… 
miR-200c, miR-107,
miR-17, miR-20b,
miR-106a, miR-301a
… 
hESC/HES2 miR-375, miR-10a, 
miR-24, miR-218, 
miR-122, miR-371-3p
… 
Let-7i, miR-302c*,
miR-409-3p, miR-187,
miR-142-3p, miR-520f
… 
hESC/H9 miR-375, miR-708, 
miR-489, miR-455-5p, 
miR-224*, miR-653
… 
miR-125b, miR-1323,
miR-96*, miR-520f,
miR-512-3p, miR-518b
… 
hESC/CyT49 miR-375, miR-708, 
miR-489, miR-371-5p, 
miR-125a-5p, miR-653
… 
miR-125b, miR-1323, 
miR-105, miR-520f, 
miR-520a-5p, miR-518b
… 
hESC/CHA4 miR-375, miR-326, 
miR-181a, miR-30a*, 
miR-532a-3p, miR-23b
… 
miR-520c-3p, miR-520f, 
miR-515-3p, miR-525-5p, 
miR-520b, miR-210
… 
Tgfbr2
miR-20a
Tgfbr2
Kat2b
miR-302b
HepatoblastHepaticendoderm
miR-30 family
Snail1
HNF6
OC2
miR-495
miR-218
27
28
28
29
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34
34
37
(a) (b)
Fig. 1. miRNAs involved in definitive endoderm (DE) formation (a), and hepatoblast migration and maturation (b). The top up/down regu-
lated miRNAs when embryonic stem cells (ESC) are induced to differentiate into DE cells were assessed in the mESC line TCL-1, and the hESC
lines HES1, HES2, H9, CyT49 and CHA4 (a). The expression levels of miR-30 family members decreased during the hepatic endoderm differ-
entiation into hepatoblasts, accordingly their target gene SNAIL1 was increased during the process. While miR-20a (targeting TGFBR2),
miR-302b (targeting TGFBR2 and KAT2B), and miR-495 and miR-219 (targeting HNF6 and OC2) showed opposite expression patterns (b).
References are listed in the figure.
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found at higher concentrations in fetal liver at e14.5 and
e16.5, at which time migration of hepatoblasts is no
longer occurring (Fig. 1b) (37).
Hepatocyte maturation
Hepatoblasts are bipotential cells, which differentiate
into hepatocytes to form the liver parenchyma, and into
cholangiocytes to form biliary ducts (2). Bipotent mur-
ine embryonic liver (BMEL) cells, which can differenti-
ate into hepatocytes and BECs in different culture
systems, are frequently used to study the mechanism
whereby hepatocytes and cholangiocytes are specified
(38). Using the BMEL cell system, Laudadio et al. found
that miR-122, the liver specific and most abundant miR-
NA, which accounts for about 70% of the total liver
miRNA population (39), directly or indirectly stimu-
lates the expression levels of 24 hepatocyte-specific
genes. Forced expression of miR-122 in transgenic mice
promoted HNF6 expression. Moreover, HNF6 stimu-
lated the expression of miR-122 by directly binding to
its promoter during liver development (40). This data
indicates that a positive feed-back loop between miR-
122 and HNF6 regulates proper hepatocyte-specific gene
expression. Deng et al. demonstrated that forced expres-
sion of miR-122, during differentiation of mESCs to he-
patocytes from day 12 onwards, significantly increased
the levels of hepatocyte indocyanine green (ICG)
uptake, glycogen staining, urea synthesis, ammonia
elimination, albumin expression and cytochrome P450
(CYP) metabolism (41). They further showed that high
levels of miR-122 may indirectly lead to up-regulation
of forkhead box A1 (FOXA1) and hepatocyte nuclear
factor 4, alpha (HNF4A), two liver-specific transcription
factors. miR-122, FOXA1 and HNF4A also form a posi-
tive feedback loop to promote hepatocyte maturation.
miR-122 is down-regulated upon transformation and
re-expression of miR-122 in the human liver cancer cell
line HepG2 suppressed cellular proliferation and
enhanced hepatocyte functions (42). These studies thus
suggest that miR-122 is a key regulator to maintain the
balance between hepatocyte proliferation and differenti-
ation. Furthermore, miR-122 showed down-regulation
in HCC cells, restoration of miR-122 can suppress cell
proliferation and tumour metastasis (43). A list of miR-
NAs has potential clinical implications related to the
processes of liver development and metabolism can be
found in Table 1.
Gailhouste et al. cultured E-cadherin positive cells
isolated from mouse fetal liver to gain insight in matu-
ration of hepatocytes (44). They found that forced-
expression of miR-148a also enhanced the expression
level of some hepatic marker genes. Target analysis iden-
tified that miR-148a directly inhibits the expression of
DNA (cytosine-5-)-methyltransferase 1 (DNMT1), the
major DNA methylation enzyme, which prevents cell
maturation.
Other mature hepatic genes include transporters for
bile salts and phospholipids, such as ATP-binding cas-
sette sub-family B member 11 (ABCB11) and ATPase
aminophospholipid transporter class I type 8B member
1 (ATP8B1) (45,46). Allen et al. identified ABCB11 and
ATP8B1 as two direct targets of miR-33 (47). Forced
expression of miR-33 significantly decreased biliary out-
put, while silencing of miR-33 increased sterols in bile
and enhanced reverse cholesterol transport. Notably,
silencing of miR-33 can rescue simvastatin and lithogen-
ic diet induced cholestasis and liver damage (47), which
suggests miR-33 is a potential therapeutic target for
cholesterol metabolism related diseases.
Table 1. Potential clinical significance of some miRNAs related to liver development and metabolism
miRNAs Process Potential clinical significance Reference
miR-30 family Hepatoblast migration and
maturation
Therapeutic target to suppress EMT (32)
miR-122 Hepatocyte maturation Biomarker for liver injury, therapeutic target to
supress cell proliferation
(41, 42)
miR-33 Hepatocyte maturation Biomarker and therapeutic target for cholestasis
and statin- and diet-induced hepatotoxicity
(47)
miR-23b cluster BEC maturation Biomarker for bile duct injury (53)
miR-27a/b HSC activation and proliferation Biomarker and therapeutic target for liver fibrosis
and other diseases
(59)
miR-16/19b/29b/146a/150/
194/195/335
HSC activation and proliferation Biomarker and therapeutic target for liver fibrosis
and other diseases
(56,58,60,62,
63,124–126)
miR-34a/181a, miR-103/
107, miR-122, miR-802
Glucose and insulin metabolism Therapeutic target for obesity related diseases (71–73,82,83)
Let-7, miR-29a/b, miR-143 Glucose and insulin metabolism Therapeutic target for diabetes (76,80,81)
miR-122 Lipid metabolism Therapeutic target for lipid metabolic disease (85,86)
miR-27b Lipid metabolism Biomarker and therapeutic target for
dyslipidaemia and atherosclerosis
(94)
miR-122 Iron metabolism Biomarker and therapeutic target for hereditary
hemochromatosis
(103)
miR-93/214/699, miR-27b Detoxification Therapeutic target for anti-aging (120,121)
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In the adult, hepatocytes are quiescent, except follow-
ing liver injury where proliferation of hepatocytes
occurs to replace lost cells, or during transformation to
HCC (48–50). Numerous miRNAs have been shown to
play a role in controlling hepatocyte proliferation dur-
ing liver regeneration, including miR-21/23b/221,
among others (Table 2). Jung et al. identified a group
of miRNAs, including miR-106a/106b/17/93/301a/130b
that are expressed significantly more in HCC and hESCs
than in mature quiescent hepatocytes (51). These miR-
NAs promote hepatocyte proliferation/transformation
by regulating phosphatase and tensin homolog (PTEN)
and TGFb tumour suppressor pathways (51).
These studies all point to the critical role miRNAs
play in maintaining mature hepatocytes (Table 2), even
if many mechanistic studies are yet to be performed to
fully understand the mechanisms underlying the miR-
NA-mediated hepatocyte homeostasis.
Table 2. MicroRNAs Involved in Hepatocyte, BEC and HSC development
miRNAs Tissue/cell type Target genes Function References
Hepatocyte development
miR-122 BMEL – Forms a positive feedback loop with HNF6
to regulate hepatocyte differentiation
(40)
CCL-9.1 – Regulates hepatic differentiation and
maturation
(41)
C57BL/6J mouse liver and
human/HepG2, Huh-7
CUL1 Regulates hepatocyte proliferation and
differentiation
(42)
miR-148a Mouse/Fetal Hepatoblast and
human/HepG2, Hep3B, Huh-7
DNMT1 Promotes hepatic differentiation (44)
miR-33 C57BL/6 mouse liver and
human/Huh-7
ABCB11 ATP8B1 Regulates hepatocyte biliary transportation (47)
Hepatocyte proliferation during liver regeneration
miR-21 Mouse and rat liver PELI1
BTG2
Promotes hepatocyte proliferation (127–130)
miR-23b Rat liver and BRL-3A SMAD3 Promotes hepatocyte proliferation (131)
miR-26a Mouse liver CCND2 CCNE2 Inhibits hepatocyte proliferation (132)
miR-33 Mouse liver and A549, Huh-7 CDK6
CCND1
Inhibits hepatocyte proliferation (122)
miR-34a Rat liver INHBB
MET
Inhibits hepatocyte proliferation (133)
miR-127 Rat liver BCL6
SETD8
Inhibits hepatocyte proliferation (134)
miR-221 Mouse liver P27
P57
ARNT
Promotes hepatocyte proliferation (135)
BEC development
miR-23b,
miR-27b,
miR-24-1
HBC-3 SMAD3, 4, 5 Repressing bile duct gene expression (53)
miR-30a Zebra fish AK1
TNRC6a
Required for biliary development (54)
HSC development
miR-27a, b Rat HSC RXRa Promotes HSC proliferation and inhibits
lipid accumulation
(59)
miR-29b Human, mouse HSC COL1A1 Inhibits HSC activation and proliferation (60,125,126)
miR-150 Human HSC COL1A1
COL4A4
c-MYB
Inhibits HSC activation and proliferation (62,63)
miR-194 Human HSC RAC1 Inhibits HSC activation and proliferation (63)
miR-15b Rat HSC BCL2 Promotes HSC apoptosis (136)
miR-16 Rat HSC CD-1
BCL2
Inhibits HSC proliferation and promoting
apoptosis
(136)
miR-19b Human and rat HSC TGFBRII Inhibits HSC activation and proliferation (56)
miR-146a Rat HSC SMAD4 Inhibits HSC proliferation and promotes
apoptosis
(137)
miR-195 Human HSC Cyclin E1 Inhibits HSC activation and proliferation (58)
miR-335 Rat HSC TNC Inhibits HSC proliferation and migration (124)
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BEC maturation
Cholangiocytes, or bile duct epithelial cells (BECs) are,
like hepatocytes, of endodermal origin. BECs line the in-
terlobular and extrahepatic bile ducts. As is true for he-
patocytes, multiple studies have assessed the role of
miRNAs in BEC diseases, such as cholangiocarcinoma,
polycystic liver disease and primary biliary cirrhosis
[reviewed in (52)], although much less is known regard-
ing the role miRNAs during BEC development. BEC
specification from hepatoblasts is mediated by both
NOTCH and TGFb signalling. Studies using the murine
fetal hepatoblast cell line, HBC-3, showed that TGFb
receptors and SMADs (key signal transduction mole-
cules for TGFb) are down-regulated during differentia-
tion towards hepatocytes but induced during BEC
differentiation (53). miR-23b (aside from miR-27b and
miR-24-1) was identified as directly targeting SMAD 3,
4 and 5. Knockdown of miR-23b under hepatocytic
differentiation conditions of HBC-3 cells promoted
expression of bile duct genes, while forced expression of
miR-23b under bile duct differentiation conditions
repressed the process. In situ hybridization analysis
confirmed miR-23b to only be expressed in developing
hepatocytes, but not in the ductal plates (53). These
results suggest that miR-23b is involved in regulating
lineage specification of hepatocytes and cholangiocytes
by influencing the TGFb signalling pathway. On the
contrary, the miR-30 family members, miR-30a and
miR-30c were identified specifically expressed in ductal
plates. Knock-down of miR-30a in the Zebrafish larva
caused defective biliary development (54). Together,
these studies also exemplify the importance of miRNA
mediated regulation of hepatocyte vs. BEC specification,
even if many more studies will be needed to fully under-
stand the mechanisms involved in miRNA-mediated
BEC development (Table 2).
HSC and LSEC development
HSCs are derived from mesoderm, even if little is
known on how HSCs are specified and differentiate.
Hence, no data is available on miRNAs that play a role
in HSC generation. However, much is known regarding
the mechanisms underlying HSC activation into prolif-
erative, fibrogenic and contractile myofibroblasts (55),
including miRNAs that modify TGFb signalling (56,57)
and IFN signalling (58) in HSCs. Down-regulation of
miR-27a and 27b induced retinoid X receptor-a expres-
sion and induced a quiescent state of activated HSCs,
including restoration of cytoplasmic lipid droplets and
decreased cell proliferation (59). Forced expression of
miR-29 in HSCs inhibits collagen type I production by
targeting COL1A1 (60,61), while forced expression of
miR-150 inhibits both collagen type I and type IV by
directly binding to SP1 and COL4A4 (62). Venugopal
et al. found that forced expression of miRNA-150 and
miRNA-194 inhibited HSC activation and ECM
production by inhibiting c-MYB and ras-related C3 bot-
ulinum toxin substrate 1 (RAC1) expression respectively
(63). A list of miRNAs known to play a role in the HSC
quiescence vs. activation can be found in Table 2.
Whether miRNAs play a role in the development of
LSECs is largely unknown. Some studies have identified
miRNAs that play a role in LSEC based diseases, includ-
ing alcoholic or drug induced liver disease and idio-
pathic portal hypertension among others (64–66).
MicroRNAs in liver metabolism
Glucose metabolism
Plasma glucose levels are dynamic, and are tightly con-
trolled by insulin and glucagon. Insulin is secreted in
response to high glucose levels by pancreatic b-cells and
acts on hepatocytes to stimulate glucose uptake and
store glucose as glycogen (67). On the contrary, gluca-
gon is secreted by pancreatic a-cells and promotes the
degradation of glycogen to glucose when blood glucose
levels decrease (68).
As described above, global loss of miRNAs in the liver
causes severe liver dysfunction (25). These studies also
demonstrated that miRNAs are involved in the regula-
tion of glucose metabolism. Conditional deletion of the
miRNA processing enzyme DICER1 in mouse liver
resulted in severe hypoglycaemia in the fasting state
because of the depletion of glycogen. Loss of Dicer was
associated with loss of miR-122/148a/192/194 expres-
sion (23). Which of these miRNAs are specifically
involved in glucose homeostasis remains to be deter-
mined.
Besides the studies in DICER1 null hepatocytes, many
reports have indeed shown a critical role of specific
miRNAs in regulating glucose metabolism in the liver.
Glucose-6-phosphatase (G6PC) hydrolyses glucose 6-
phosphate to an inorganic phosphate and free glucose;
therefore it is an important enzyme in glucose homeo-
stasis. A maternal low-protein (LP) diet during preg-
nancy caused a higher expression level of G6PC in the
liver of male but not female piglets. Further analysis
showed two significantly up-regulated miRNAs (only in
female piglets) ssc-miR-339-5p and ssc-miR-532-3p,
which directly target G6PC (69). When blood glucose
level is high, glucose will be stored as glycogen via gluco-
neogenesis mediated part by insulin signalling. Sirtuin-1
(SIRT1) is a positive regulator of insulin signalling
in many cell types, including hepatocytes (70). Two
miRNAs, miR-34a and miR-181a can target the 30-UTR
of SIRT1 and inhibit its expression (71,72). Ectopic
expression of miR-181a impaired hepatic insulin signal-
ling glucose, while inhibition of miR-181a improved
homeostasis in diet-induced obese mice (Fig. 2) (72).
The liver specific miR-122 was also found involved in
regulating insulin signalling. Yang et al. identified that
miR-122 was down-regulated in high-fat-diet-fed mice
or hepatocyte models of insulin resistance (73). Further
Liver International (2014)
© 2014 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd 981
Chen and Verfaillie miRNAs regulate liver development
analysis showed miR-122 can directly target protein
tyrosine phosphatase 1B (PTP1B), the inhibitor of hepa-
tic insulin signalling, by dephosphorylating tyrosine
residues in IR and IRS. The modified antisense agents or
antagomir of miR-122 have already been used to against
HCC (74) and/or HCV (75), however, the clinical trial
for miR-122 on glucose metabolism related diseases
should be further explored.
A recent study uncovered a link between the Lin28/
let-7 pathway and glucose metabolism (76). Transgenic
mice wherein both Lin28a and Lin28b were ectopically
expressed had enhanced insulin sensitivity and glucose
tolerance; while loss of Lin28a or forced expression of
let-7 resulted in enhanced insulin tolerance and glucose
intolerance (76). These effects occured partly because of
let-7-mediated repression of the components of initial
steps in the insulin-PI3K-mTOR pathway, including
IGF1R, IR and IRS2. In addition to let-7, other miRNAs
have been identified to regulate the initial steps in insu-
lin-mediated glucose regulation, including miR-144,
which targets IRS1 in a Type 2 Diabetes mellitus (T2D)
rat model (77), and miR-33 that targets IRS2 in HepG2
and Huh7 cells (78).
miR-126 was found to target both IRS1 and PI3KR2,
a regulatory component of PI3K in the SK-Hep1 cells
(79). A study in white adipocytes and liver of diabetic
rats demonstrated that up-regulation of miR-29a/b
inhibits AKT (a key enzyme in the insulin-signalling
pathway) activation and leads to impaired glucose
homeostasis (80). Another miRNA, miR-143 was identi-
fied as an indirect regulator of AKT (81). Forced expres-
sion in hepatocytes of miR-143 caused impaired
insulin-stimulated AKT activation and glucose tolerance
in db/db mice. Subsequent analysis revealed that oxys-
terol-binding-protein-related protein 8 (ORP8), which
regulates AKT activation, is a direct target of miR-143
(81).
Another study exploiting obese mice, found that
miR-103/107/802 were more highly expressed in obese
than WT mice (82,83), Silencing of miR-103/107
improved glucose homeostasis and insulin sensitivity in
the liver and adipose tissue. Conversely, forced expres-
sion of miR-103/107 in either liver or fat resulted in an
increase of fasting blood-glucose and insulin levels.
Caveolin-1 (CAV1), a critical regulator of the insulin
receptor, was identified as a direct target gene of miR-
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Fig. 2. miRNAs involved in glucose homeostasis. The initial steps of the insulin signalling pathway are tightly controlled by miRNAs, such as
miR-103/107 targeting CAV1, miR-144 and miR-126 targeting IRS1, miR-122 targeting PTP1B which further inhibits IR and Lin28/let-7 regu-
lating IRS2 and IGF1R. The downstream PI3K/AKT signalling is also controlled by miRNAs, such as miR-126 targeting PI3KR2, miR-143 target-
ing ORP8 to affect AKT and miR-29 directly targeting AKT. AKT controls glucose transportation by regulating GLUT4. In the glucose
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by targeting SIRT1. miR-802 inhibits HNF1b and its downstream genes related to glucose tolerance and insulin sensitivity. References are
listed in the figure.
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103/107. Silencing of miR-103/107 in CAV1 null mice
did not improve insulin sensitivity (83). Moreover,
Dicer has been reported as a direct target of miR-103/
107 (84), Therefore, up-regulation of miR-103/107
resulting in a low level of DICER may aggravate the glu-
cose tolerance impairment, as described in the condi-
tional DICER knock-out mice (25). mi-802 had a
similar effect on glucose homeostasis and insulin sensi-
tivity as miR-103/107 in inducible overexpression or
knock-down studies (82). Further analysis confirmed
HNF1b, a member of the homeodomain-containing
superfamily of liver-enriched transcription factors as a
direct target of miR-802. Inhibition of hepatic HNF1b
impaired insulin signalling and promoted hepatic gluco-
neogenesis (82).
Together, these results indicate that the glucose
metabolism and the insulin signalling pathway in he-
patocytes (and adipose cells) are tightly regulated by
miRNAs (Fig. 2).
Lipid metabolism
MicroRNA-122 was the first miRNA identified to regu-
late lipid metabolism in 2006 (85). Esau et al. found
that inhibition of miR-122 with antagomirs reduced
plasma cholesterol levels and increased fatty-acid oxida-
tion, which resulted in a decrease of hepatic fatty-acid
and cholesterol synthesis rates (85). Down-regulation of
miR-122 also decreased low density lipoprotein (LDL)
and high density lipoprotein (HDL) fractions both in
liver and blood (86). Interestingly, miR-370 was identi-
fied to have similar effects on lipid metabolism by
down-regulating miR-122 and carnitine palmitoyl trans-
ferase 1a (CPT1a), an enzyme that promotes fatty acid
b-oxidation (87). miR-33 was also identified to regulate
cholesterol homeostasis via targeting the sterol trans-
porter proteins, ABCA1, ABCG1 and NPC1 (88), and
fatty acids metabolism via targeting CROT, CPT1a,
HADHB and AMPKa (89). Scavenger receptor class B
member 1 (SR-BI) that regulates selective uptake of
high-density lipoprotein cholesterol (HDL-C) (a step of
reverse cholesterol transport) (90) is inhibited by miR-
185, miR-96 and miR-223, which repress selective HDL-
C uptake (91). Angiopoietin-like 3 (ANGPTL3) and
glycerol-3-phosphate acyltransferase (GPAM) are two
genes implicated in the regulation of lipid metabolism
(92,93). miR-27b targets these two genes and their
expression levels are inversely altered in a mouse model
of dyslipidaemia (94). More recently, miR-1 and miR-
206 were identified to suppress lipogenesis via directly
targeting liver X receptor alpha (LXRa), a nuclear hor-
mone receptor critical for transcriptional control of
lipid metabolism (95). These results indicate that as in
glucose metabolism, miRNAs play important roles in
regulating lipid metabolism and suggest miRNAs may
be used as therapeutic targets for metabolic diseases
(Fig. 3).
Proanthocyanidins, mainly present in many fruits
including grapes, can improve human health via multi-
ple activities (96). A grape seed proanthocyanidin
extract (GSPE) was shown to regulate lipid metabolism
and correct dyslipidaemia associated with dietary obes-
ity in rats (97,98). GSPE was identified to promote
hepatic cholesterol efflux to produce new HDL com-
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Fig. 3. miRNAs involved in lipid metabolism. Leishmania donovani surface protein GP63 targets DICER1 to inhibit its downstream miRNAs,
such as miR-122 which affects fatty-acid and HDL/LDL metabolism. miR-370 inhibits CPT1a directly and miR-122 indirectly to regulate fatty-
acid and HDL/LDL metabolism. Proanthocyanidins (GSPE) regulate fatty acid oxidation, HDL/LDL and cholesterol metabolism via inhibiting
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References are listed in the figure.
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plexes by repressing miR-33 and reduce lipogenesis by
repressing miR-122 in vivo and in vitro (99). Not only
mammals, but also Leishmania donovani, can take
advantage of miRNAs to regulate lipid metabolism.
L. donovani infects liver and spleen and thus causes
visceral leishmaniasis (100). High serum cholesterol
causes resistance to L. donovani infection (101), while
L. donovani infected liver contains low levels of choles-
terol and altered expression of lipid metabolic genes,
many of which are direct or indirect targets of miR-122.
Glycoprotein GP63, a Zn-metalloprotease on the surface
of L. donovani, targets DICER1 to prevent miRNA pro-
duction, including miR-122 (102). Hence, L. donovani
exploits the host liver metabolism to aid in infection by
suppressing Dicer and down-streaming miRNAs that
lower cholesterol levels (Fig. 3).
Iron metabolism
Liver is the central organ to control iron homeosta-
sis through synthesis of the peptide hormone hepci-
din (encoded by HAMP), the key factor of duodenal
iron absorption and release. Specific depletion of
miR-122 caused systemic iron deficiency in mice
(103). This is consistent with the low expression lev-
els of miR-122 in a mouse model of hereditary hae-
mochromatosis and in liver biopsies of patients with
hereditary haemochromatosis (103). At the molecular
level, miR-122 inhibition increased mRNA levels of
genes that control systemic iron levels, including
haemochromatosis (HFE), haemojuvelin (HJV), bone
morphogenetic protein receptor type 1A (BMPR1a)
and HAMP. HFE and HJV have been confirmed to
be direct targets of miR-122 (103).
Forced expression of miR-485-3p in HepG2 cells
was associated with increased cellular iron levels, while
inhibition of miR-485-3p decreased cellular iron con-
tent. Moreover, the only known mammalian cellular
iron exporter – ferroportin (FPN), was shown to be
targeted by miR-485-3p (104). Hence, iron cellular
export may be a miRNA-mediated process. MicroRNAs
may also be involved in protecting hepatocytes from
oxidant injury via regulating iron reutilization as let-7
directly targets the haeme-regulated transcriptional
repressor basic leucine zipper transcription factor 1
(BACH1), resulting in a de-repression of the BACH1
target haeme oxygenase (HMOX1) (105), the key
enzyme in iron reutilization (106). The function of
miRNAs in iron metabolism has also been demon-
strated to regulate iron acquisition, iron storage and
iron utilization by the studies in other cell types, as well
as in several diseases (107,108).
Interestingly, iron in turn appears to affect miRNA
processing via its physiological role as the functional
component in haeme. Faller et al. described that
DGCR8 is a haeme-binding protein, and haeme-free
DGCR8 is less active than haeme-bound DGCR8 (109).
Additionally, haeme-mediated regulation of DGCR8
depends on the oxidation state of iron in haeme (110).
Therefore, both inadequate iron levels resulting in low
haeme levels, and the wrong oxidation state of iron
resulting in abnormal haeme, can decrease pri-miRNA
processing. However, high haeme levels in cells could
also affect miRNAs expression (111), but the molecular
mechanism remains to be explored. The putative role of
miRNAs in iron homeostasis in hepatocytes is summa-
rized in Figure 4.
Detoxification
The liver is the main organ for detoxification of drugs
and toxic endogenous compounds. The CYP superfam-
ily is a large and diverse group of enzymes involved in
drug metabolism and bioactivation, which are highly
expressed in the liver (112).
To investigate which miRNAs regulate genes related
to drugs and xenobiotic substances metabolism, screens
have been done using cohorts of human liver tissue.
Association analysis between the expression levels of
CYP genes and preselected miRNAs revealed that
CYP1A1 might be regulated by miR-132/142-3p/21,
CYP2A6 by miR-142-3p/21, CYP2C19 by miR-130b/
185/34a, and CYP2E1 by miR-10a/200c/let-7 g (113).
These preliminary analyses suggest that miRNAs may
directly regulate CYP expression levels in the liver, even
if proof for this hypothesis is still lacking.
Some studies have identified miRNAs that indirectly
affect CYP genes by targeting their upstream transcrip-
tion factors. The metabolism of more than 50% of all
clinically relevant drugs is catalyzed by CYP3A4 in
human (114). The expression of CYP3A4 is predomi-
nantly regulated by pregnane X receptor (PXR). Takagi
et al. found that miR-148a can directly target human
PXR (115). Thus, miR-148a may indirectly modulate
CYP3A4 levels in the liver. Another study in Zebrafish
liver showed that PXR, a regulator of the CYP3A65 gene,
was targeted by dre-miR-27b (116). CYP1A1, a phase I
enzyme in drug metabolism, was previously identified
to be regulated by aryl hydrocarbon receptor nuclear
translocator (ARNT), which is involved in biological
responses to xenobiotic exposure and hypoxia. Oda
et al. demonstrated that ARNT (protein level but not
mRNA level) is regulated by miR-24. Forced expression
of miR-24 in HuH7 and HepG2 significantly decreased
the mRNA and protein levels of CYP1A1 (117). A fur-
ther study in HepG2 cells revealed that miR-24 together
with miR-34a could directly target the liver enriched
nuclear factor HNF4a, decreasing levels of CYP7A1 and
CYP8B1, downstream genes of HNF4A (118). Some
miRNAs that can directly regulate CYP genes in other
tissue or cells are also summarized in Table 3. Together,
these studies suggest that miRNAs are directly or indi-
rectly involved in drug metabolism by regulating the
expression of CYP superfamily genes, and miRNAs may
act as potential therapeutic targets for drug-induced
liver diseases.
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The glutathione S-transferases superfamily is another
large family of enzymes that have important detoxifica-
tion roles, especially related to oxidative stress (119). By
screening liver miRNAs patterns in 4–33 month old
mice, Maes et al. identified three miRNAs, miR-93,
miR-214 and miR-699, which are up-regulated in aged
liver and may contribute to oxidative defense by target-
ing various classes of glutathione S-transferases (120).
Another comprehensive miRNA microarray study in
Ames dwarf mice, a model mouse famous for its
remarkable propensity to delay the onset of aging, iden-
tified miR-27b as a miRNA capable of suppressing orni-
thine decarboxylase (ODC) and spermidine synthase
(SRM), two key enzymes involved in ammonia and glu-
tamine metabolism (121). It is hypothesized that the
high levels of miR-27b, and consequent inhibition of its
targets in dwarf mice, may improve their detoxification
ability, and ultimately contribute to their extended
health span and longevity (121).
Conclusions
Extensive studies over the past decade have revealed that
miRNAs play critical roles in regulating multiple aspects
of liver development, including hepatic and biliary spec-
ification and differentiation, hepatocyte and HSC devel-
opment, hepatic metabolic functions, as well as the
establishment of liver zonation. The regulation shows
several features: (i) one miRNA can be involved in mul-
tiple developmental aspects. For instance, miR-33 regu-
lates hepatocyte proliferation (122), lipid metabolism
(88) and biliary secretion (47), while miR-122 regulates
hepatocyte specification and proliferation (40, 42), lipid
metabolism (85) and iron metabolism (103). (ii) Meta-
bolic pathways can be sequentially regulated by different
miRNAs. For instance, miR-339 and miR-532 inhibit
G6PC to control glucose synthesis (69), then miR-29
(80) and miR-143 (81) (via targeting ORP8) inhibit
AKT to control glucose translocation through GLUT4,
and lastly various miRNAs inhibit the insulin pathway
to influence glucose up-taking (Fig. 2). (iii) The roles of
at least some of these miRNAs are conserved. miR-122
controls hepatocyte differentiation both in Zebrafish
and mouse (40), and miR-29b suppresses HSCs activa-
tion by targeting COL1A1 both in mouse and human
(60,61).
Even if our understanding of the roles of miRNAs
in liver development is improving, some important
questions remain to be solved. (i) How do miRNAs
regulate hepatocyte maturation? The in vitro genera-
tion of hepatocyte-like cells from progenitor or stem
cells is widely being studied because of their poten-
tial application in ADME-Tox studies, hepatocyte
transplantation, and drug development for liver diseases.
However, generation in vitro of fully mature hepato-
cytes is yet to be achieved. Exploring the role of miR-
NAs important for supporting hepatocyte maturation
may provide a very promising way to improve hepato-
cyte maturation. (ii) How do specific miRNAs regulate
liver zonation? It is clear from hepatocyte specific
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Fig. 4. miRNAs involved in liver iron metabolism. Low haeme levels regulate mature miRNA production by inhibiting Drosha/DGCR8 com-
plex. Liver specific miR-122 inhibits hepcidin production by targeting HFE and HJV, the co-receptors in SMAD signalling pathways. Hepcidin
inhibits iron transportation, thereby preventing excess iron absorption. miR-485-3p inhibits iron transporter FPN. Let-7 inhibits iron re-utiliza-
tion from haeme by targeting BACH1. References are listed in the figure.
Liver International (2014)
© 2014 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd 985
Chen and Verfaillie miRNAs regulate liver development
conditional Dicer knock-out mice that miRNAs are
essential for the establishment of liver zonation. A fur-
ther exploration of the molecular mechanism of spe-
cific miRNAs in this zonation process may guide us to
generating zonated hepatocytes, which might be helpful
for creating bioartificial liver devices and for ADME-
Tox studies. Moreover, gaining knowledge in zonation
process may also help us to find solutions against liver
diseases originated from zonation-dysfunction. (iii)
Further elucidation of the role of miRNAs in metabolic
processes governed by the liver, might shed light on
innovative therapies for metabolic disorders. For
instance, initial studies have shown that ectopic expres-
sion of miR-122 may be a novel therapy for hyperlip-
idaemia in a diet-induced obesity mouse model (85) or
in human patients (123). As miRNAs are also control-
ling blood glucose levels, insights in this role might
lead to improved anti-diabetic therapies. Interestingly,
a metabolic shift is almost always observed in preneo-
plastic and neoplastic cancer cells. Therefore, identify-
ing the role of miRNAs as important regulators of
metabolism might provide a clinical perspective against
HCC.
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